DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Upcoming Events
  • Migraine | DL&F|G7

    The anti-CGRP monoclonal antibodies, the first therapies in development specifically for migraine prophylaxis, are in late-phase development. Despite extensive genericization of the migraine...

    Oct 04
  • Type 2 Diabetes | Unmet Need | G7

    Type 2 diabetes (T2D) is a critical public health concern. Even with a broad range of treatments available, there is considerable unmet need in T2D, and with a growing prevalence of the disease,...

    Oct 05
  • Asthma | Disease Landscape and Forecast | G7

            Thank you for being a valued customer. As a value-add to your report purchase, we encourage you to sign up for this exclusive analyst call. This is your chance to obtain a...

    Oct 12
  • Human Immunodeficiency Virus | Access and Reimbursement | US

    This webinar outlines the market access factors that influence the success of HIV antiretroviral therapies in the U.S. market. The webinar will focus on research that explores physician and payer...

    Oct 20
  • LOEWS PHILADELPHIA HOTEL

    Digital Pharma East

    Filed under: Industry Event - Speaking

    The conference will cover areas like the industry leaders, analysts and business strategists will also explore new possibilities in the research and marketing of pharmaceutical products. Booth...

    Oct 24-27
  • Niche & Rare Disease Landscape & Forecast | Cytomegalovirus | US/EU5

      Thank you for being a valued customer. As a value-add to your report purchase, we encourage you to sign up for this exclusive analyst call. This is your chance to obtain a deeper dive into the...

    Oct 25
  • Gastric Cancer | Disease Landscape and Forecast | G7

    With only two targeted agents currently approved, chemotherapy is the mainstay of gastric and GEJ adenocarcinoma treatment. However, the emerging therapies pipeline is buoyant, including agents from...

    Oct 26
  • Heart Failure | Disease Landscape and Forecast | G7                                                 

    The number of diagnosed AHF events and prevalent CHF cases is increasing annually. Patients are subject to high rates of mortality and morbidity. Following years of stagnation, the AHF and CHF markets...

    Oct 27
  • Austria Center Vienna

    ISPOR European Congress

    Filed under: Industry Event - Exhibiting

    Managing Access to Medical Innovation: Strengthening the Methodology-Policy Nexus

    ISPOR is recognized globally as the leading educational and scientific organization for health economics and outcomes research (HEOR) and its use in health care decisions. Booth Location: #417/418...

    Oct-Nov 29-02
  • Germany

    Bio Europe Fall

    Filed under: Industry Event - Exhibiting

    BIO-Europe® is Europe's largest partnering conference serving the global biotechnology industry. The conference annually attracts leading dealmakers from biotech, pharma and finance along with the...

    Nov 07-09
1-10 of 20